HepaStem Long-Term Safety Registry

NCT03343756 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2024-05-29

No results posted yet for this study

Summary

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences

Conditions

  • Urea Cycle Disorder
  • Crigler-Najjar Syndrome
  • Acute on Chronic Liver Failure

Sponsors & Collaborators

  • Cellaion SA

    lead INDUSTRY

Eligibility

Min Age
5 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-04
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • Belgium
  • Bulgaria
  • France
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03343756 on ClinicalTrials.gov